Genetic Alteration Profiling in North Macedonian Lung Cancer Patients
Authors:
- Aleksandar EftimovAEAleksandar Eftimov
- Rubens JovanovicRJRubens Jovanovic
- Slavica Kostadinova KunovskaSKSlavica Kostadinova Kunovska
- Magdalena Bogdanovska TodorovskaMTMagdalena Bogdanovska Todorovska
- Boro IlievskiBIBoro Ilievski
- Panche ZdravkovskiPZPanche Zdravkovski
- Selim KominaSKSelim Komina
- Blagica KrstevskaBKBlagica Krstevska
- Simonida CrvenkovaSCSimonida Crvenkova
- Marija SimonovskaMSMarija Simonovska
- Gordana PetrushevskaGPGordana Petrushevska
Open Access
Abstract
Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer—BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA. Methods: Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations. Results: Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected. Conclusions: Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective.Keywords
This publication has 63 references indexed in Scilit:
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2021
- OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-JapanJournal of Thoracic Oncology, 2019
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancerDrug Resistance Updates, 2019
- Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLCJournal of Thoracic Oncology, 2018
- ROS1-rearranged Non–Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic DilemmasClinical Lung Cancer, 2018
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerJournal of Thoracic Oncology, 2017
- Genetic alterations defining NSCLC subtypes and their therapeutic implicationsLung Cancer, 2013
- The global burden of disease due to occupational carcinogensAmerican Journal of Industrial Medicine, 2005
- Pulmonary Resection After Curative Intent Radiotherapy (>59 Gy) and Concurrent Chemotherapy in Non–Small-Cell Lung CancerThe Annals of Thoracic Surgery, 2004